JP7578602B2 - Ｐ２ｘ３修飾薬での治療 - Google Patents

Ｐ２ｘ３修飾薬での治療 Download PDF

Info

Publication number
JP7578602B2
JP7578602B2 JP2021549617A JP2021549617A JP7578602B2 JP 7578602 B2 JP7578602 B2 JP 7578602B2 JP 2021549617 A JP2021549617 A JP 2021549617A JP 2021549617 A JP2021549617 A JP 2021549617A JP 7578602 B2 JP7578602 B2 JP 7578602B2
Authority
JP
Japan
Prior art keywords
alkyl
group
hydrogen
compound
endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549617A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020174283A5 (enExample
JP2022521955A (ja
Inventor
アントニオス・マッゾラニス
デニス・ガルソー
ロベルト・ベリーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 3 Ltd filed Critical GlaxoSmithKline Intellectual Property No 3 Ltd
Publication of JP2022521955A publication Critical patent/JP2022521955A/ja
Publication of JPWO2020174283A5 publication Critical patent/JPWO2020174283A5/ja
Application granted granted Critical
Publication of JP7578602B2 publication Critical patent/JP7578602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021549617A 2019-02-25 2020-02-24 Ｐ２ｘ３修飾薬での治療 Active JP7578602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810163P 2019-02-25 2019-02-25
US62/810,163 2019-02-25
PCT/IB2020/000160 WO2020174283A1 (en) 2019-02-25 2020-02-24 Treatment with p2x3 modulators

Publications (3)

Publication Number Publication Date
JP2022521955A JP2022521955A (ja) 2022-04-13
JPWO2020174283A5 JPWO2020174283A5 (enExample) 2023-02-24
JP7578602B2 true JP7578602B2 (ja) 2024-11-06

Family

ID=72239247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549617A Active JP7578602B2 (ja) 2019-02-25 2020-02-24 Ｐ２ｘ３修飾薬での治療

Country Status (8)

Country Link
US (1) US12485125B2 (enExample)
EP (1) EP3930722A4 (enExample)
JP (1) JP7578602B2 (enExample)
CN (1) CN113727716A (enExample)
AU (1) AU2020228760A1 (enExample)
CA (1) CA3131312A1 (enExample)
IL (1) IL285772A (enExample)
WO (1) WO2020174283A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) * 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
GB202212749D0 (en) * 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
JP2013511517A (ja) 2009-11-18 2013-04-04 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール化合物及びその使用
JP2016506935A (ja) 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
JP2017537122A (ja) 2014-12-09 2017-12-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH503559A (de) 1969-02-26 1971-02-28 Arx Paul Von Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
US9937815B2 (en) 2013-08-15 2018-04-10 Volvo Truck Corporation Method and arrangement for balancing an energy storage system
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
WO2017058645A1 (en) 2015-09-29 2017-04-06 Afferent Pharmaceuticals, Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
EP3430000B1 (en) 2016-03-14 2022-12-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3528813B1 (en) 2016-09-30 2025-04-16 ABS Development 1, Inc. P2x3 and/or p2x2/3 compounds and methods
HUE071480T2 (hu) * 2018-11-13 2025-08-28 Glaxosmithkline Intellectual Property No 3 A P2X3-modulátor metil (S)-2-((2-(2,6-difluoro-4-(metil-karbamoil)fenil)-7-metilimidazo[1,2-a] piridin-3-il)metil)morfolin-4-karboxilát kristályos formái
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2019416589B2 (en) 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
US20230101612A1 (en) 2020-02-14 2023-03-30 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511517A (ja) 2009-11-18 2013-04-04 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール化合物及びその使用
WO2012158117A1 (en) 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
JP2016506935A (ja) 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
JP2017537122A (ja) 2014-12-09 2017-12-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int. J. Nanomedicine，2017年，vol.12，pp.8171-8183，10.2147/IJN.S146569

Also Published As

Publication number Publication date
IL285772A (en) 2021-10-31
US20210386751A1 (en) 2021-12-16
CA3131312A1 (en) 2020-09-03
WO2020174283A1 (en) 2020-09-03
US12485125B2 (en) 2025-12-02
CN113727716A (zh) 2021-11-30
AU2020228760A1 (en) 2021-09-23
EP3930722A1 (en) 2022-01-05
EP3930722A4 (en) 2022-12-28
JP2022521955A (ja) 2022-04-13

Similar Documents

Publication Publication Date Title
JP7578602B2 (ja) Ｐ２ｘ３修飾薬での治療
JP7242681B2 (ja) 選択的ｐ２ｘ３修飾薬
US7169797B2 (en) Protein-tyrosine phosphatase inhibitors and uses thereof
US20230365542A1 (en) Selective Agonists of 5-HT2A Receptor and Methods of Use
US20240299404A1 (en) Treatment of pruritus with p2x3 modulators
EP1908753B1 (en) Novel heterocyclidene acetamide derivative
WO2009038204A1 (ja) 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
JP2006515587A (ja) 性的不能を治療する方法
HRP980398A2 (en) 5H-THIAZOLO /3,2-a/ PYRIMIDINE DERIVATIVES
EP2040703B1 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
EP2887804B1 (en) Cycloalkanyl[b]indoles useful as glp-1 modulators
JP2022509206A (ja) Ｍａｇｌ阻害剤による疾病の治療方法
CN115068468B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
JPWO2010050577A1 (ja) シクロヘキサン誘導体及びその医薬用途
US20050136444A1 (en) Treating neuropathic pain with neuropeptide FF receptor 2 agonists
KR20210120020A (ko) Magl 저해제에 의해 질병을 치료하는 방법
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6903132B2 (en) Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
EP2303264B1 (en) Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives
EP2565184B1 (en) Therapeutic agent and preventative agent for alzheimer's disease
JPH0770013A (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
JP4303474B2 (ja) 医薬活性のある化合物及び使用方法
FR2915100A1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
CS233746B2 (en) Processing of amidazolin derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240610

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241024

R150 Certificate of patent or registration of utility model

Ref document number: 7578602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150